-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TGdcPGLMqc60ZK+BMR395shmlCYqyVdQTE52ZbvRpk2LSxa/zjZ12Wo1VaQxMFnK EzY8cHbNuRZ/Q/OUHWVBXQ== 0001193125-03-020673.txt : 20030717 0001193125-03-020673.hdr.sgml : 20030717 20030717160525 ACCESSION NUMBER: 0001193125-03-020673 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030710 ITEM INFORMATION: Changes in registrant's certifying accountant ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030717 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MOORE MEDICAL CORP CENTRAL INDEX KEY: 0000074691 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 221897821 STATE OF INCORPORATION: DE FISCAL YEAR END: 0102 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08903 FILM NUMBER: 03791373 BUSINESS ADDRESS: STREET 1: PO BOX 1500 STREET 2: 389 JOHN DOWNEY DR CITY: NEW BRITAIN STATE: CT ZIP: 06050 BUSINESS PHONE: 2038263600 MAIL ADDRESS: STREET 1: 389 JOHN DOWNEY DRIVE CITY: NEW BRITAIN STATE: CT ZIP: 06050 FORMER COMPANY: FORMER CONFORMED NAME: OPTEL CORP DATE OF NAME CHANGE: 19850611 8-K 1 d8k.htm MOORE MEDICAL CORPORATION FORM 8-K MOORE MEDICAL CORPORATION FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 10, 2003

 

 

Moore Medical Corp.

(Exact name of registrant as specified in its charter)

 

 

Delaware

  

1-8903

  

22-1897821

(State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

389 John Downey Drive P.O. Box 1500, New Britain, CT

  

06050

(Address of principal executive offices)   (Zip Code)

 

 

Registrant’s telephone number, including area code

(860) 826-3600

 

 

(Former name or former address, if changed since last report.)

Item 4.    Change in Registrant’s Certifying Accountant

 

In accordance with Item 304 of Regulation S-K, the following information pertains to the change in Registrant’s Certifying Accountant:

 

On July 10, 2003, the Board of Directors of Moore Medical Corp. (the “Company”), upon recommendation of the Audit Committee, dismissed PricewaterhouseCoopers LLP as the Registrant’s certified public accountants and engaged Deloitte & Touche LLP to serve as the Registrant’s certified public accountants to audit the Registrant’s financial statements for the fiscal year ending December 27, 2003.

 

The reports of PricewaterhouseCoopers LLP on the Company’s consolidated financial statements for the fiscal years ended December 28, 2002 and December 29, 2001 did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles.

 

During the fiscal years ended December 28, 2002 and December 29, 2001 and through the filing date of this Current Report on Form 8-K, there were no disagreements with PricewaterhouseCoopers LLP on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not resolved to the satisfaction of PricewaterhouseCoopers LLP, would have caused them to make reference to the subject matter of such disagreement in connection with its report for the fiscal years ended December 28, 2002 and December 29, 2001.

 

There were no reportable events, as defined in Item 304(a)(1)(v) of Regulation S-K, that occurred during either of the Registrant’s fiscal years ended December 28, 2002 or December 29, 2001 or during the subsequent interim period through July 10, 2003.

 

During the Company’s two most recent fiscal years and through the date of this Form 8-K, the Company did not consult Deloitte & Touche LLP with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, or any other matters or reportable events listed in Items 304(a)(2)(i) and (ii) of Regulation S-K.

 

The Company has requested that PricewaterhouseCoopers LLP furnish it with a letter addressed to the SEC stating whether or not it agrees with the above statements. A copy of such letter, dated July 14, 2003, is filed as Exhibit 16 to this Form 8-K, evidencing its agreement with the statements set forth in this report.

 

Item 7.    Financial Statements and Exhibits

 

(c) Exhibits:

 

  16.   Letter from PricewaterhouseCoopers LLP to the Securities and Exchange Commission dated July 14, 2003.

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

    Moore Medical Corp.
Date:    July 17, 2003  

/s/    LINDA M. AUTORE

   

Linda M. Autore

President and Chief Executive Officer

EXHIBIT INDEX

 

  16.   Letter from PricewaterhouseCoopers LLP to the Securities and Exchange
         Commission dated July 14, 2003.
EX-16 3 dex16.htm LETTER FROM PRICEWATERHOUSECOOPERS LLP LETTER FROM PRICEWATERHOUSECOOPERS LLP

Exhibit 16

 

 

July 14, 2003

 

Securities and Exchange Commission

450 Fifth Street, N.W.

Washington, D.C. 20549

 

 

Commissioners:

 

We have read the statements made by Moore Medical Corp. (copy attached), which we understand will be filed with the Commission, pursuant to Item 4 of Form 8-K, as part of the Company’s Form 8-K report dated July 10, 2003. We agree with the statements concerning our Firm in such Form 8-K.

 

Very truly yours,

 

 

/s/    PRICEWATERHOUSECOOPERS LLP

-----END PRIVACY-ENHANCED MESSAGE-----